Cardiology & Vascular drugs

71 results

  • adcirca

    (Tadalafil)
    United Therapeutics Corporation
    ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity. It has been primarily studied in patients with NYHA Functional Class II-III symptoms, including cases of idiopathic or heritable PAH and PAH linked to connective tissue diseases.

  • adempas

    (riociguat)
    Bayer HealthCare Pharmaceuticals Inc.
    Adempas is indicated for adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or if inoperable, as well as for pulmonary arterial hypertension (PAH). It improves exercise capacity, WHO functional class, and delays clinical worsening. The drug is effective as monotherapy or in combination with other treatments.

  • asclera

    (POLIDOCANOL)
    Methapharm, Inc
    Asclera® (polidocanol) is indicated for the sclerotherapy of uncomplicated spider veins (≤1 mm) and reticular veins (1 to 3 mm) in the lower extremities. It is not approved for use in varicose veins greater than 3 mm in diameter.

  • astagraf xl

    (tacrolimus extended-release capsules)
    Astellas Pharma US, Inc.
    ASTAGRAF XL® is indicated for the prevention of organ rejection in kidney transplant patients, used in conjunction with other immunosuppressants for both adults and pediatric patients who can swallow capsules intact.

  • atorvaliq

    (ATORVALIQ)
    CMP Pharma, Inc.
    ATORVALIQ is indicated to reduce the risk of cardiovascular events in adults with risk factors for coronary heart disease, type 2 diabetes, and clinically evident coronary heart disease. It also lowers LDL cholesterol in various conditions, including primary hyperlipidemia and familial hypercholesterolemia, as an adjunct to diet or other therapies.

  • azor

    (amlodipine besylate and olmesartan medoxomil)
    Daiichi Sankyo Inc.
    Azor is indicated for treating hypertension to lower blood pressure, either alone or with other antihypertensive agents. Effective blood pressure reduction reduces the risk of cardiovascular events such as strokes and heart attacks, with a focus on comprehensive cardiovascular risk management. Individual treatment plans should consider patient's specific risks.

  • benicar

    (olmesartan medoxomil)
    Cosette Pharmaceuticals, Inc.
    Benicar is indicated for treating hypertension in adults and children aged six and older to lower blood pressure, reducing the risk of cardiovascular events like strokes and heart attacks. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.

  • benicar hct

    (olmesartan medoxomil-hydrochlorothiazide)
    Cosette Pharmaceuticals, Inc.
    BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension to lower blood pressure. It is not intended for initial therapy and may be used alone or with other antihypertensive medications to reduce cardiovascular risk, including strokes and myocardial infarctions.

  • brilinta

    (Ticagrelor)
    AstraZeneca Pharmaceuticals LP
    BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also reduces the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients and ischemic stroke/TIA patients.

  • bystolic

    (nebivolol hydrochloride)
    Allergan, Inc.
    BYSTOLIC is indicated for the treatment of hypertension to lower blood pressure. It can be used alone or with other antihypertensive agents, aiming to reduce the risk of cardiovascular events such as strokes and myocardial infarctions as part of comprehensive cardiovascular risk management.